Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Why now is great time to buy exposure to biotechnology

The biotechnology sector should be a major beneficiary of an ageing world population and strained government health budgets as companies develop new drugs to treat chronic diseases.
After underperforming the major indices since the end of the pandemic, the NBI (Nasdaq Biotechnology Index) offers great relative value and the prospect of superior earnings growth.
The sector trades at a 18% PE (price to earnings) ratio discount to the S&P 500, and at a 26% discount to its historical 10-year average PE, according Yardeni Research.
The current rating and negative sentiment look anomalous against the backdrop of superior earnings growth which has averaged 15% a year over the last decade.
It is no surprise to investment managers at International Biotechnology Trust (IBT) Ailsa Craig and Marek Poszepczynski who have argued the sector is characterised by big up and down cycles.
Given the cutting-edge science which companies in the sector are developing it is understandable to see periods of over-exuberance followed by big downturns and an exit of capital.
In turn, rock-bottom valuations attract mergers and acquisitions which starts the cycle all over again, leading to the next up-cycle.
The current down cycle has been exacerbated by the speculative interest in the sector during the pandemic.
Even large successful firms such as leading vaccine maker Moderna (MRNA:NASDAQ) which discovered the first Covid-19 vaccine based on mRNA technology have had a rough two years.
After leaping over 10-fold during the pandemic the shares have lost 78% of their value since August 2021.
Craig and Poszepczynski believe the sector remains unloved but sense winds of change as the trust has started to benefit from predatory interest in the sector with six companies being ‘picked-off’ over the last few months and Eli Lilly (LLY:NYSE) has just announced the $1.4 billion takeover of cancer biotech Point Biopharma (PNT:NASDAQ).
While buying individual biotech companies is not for the faint hearted and best left to the professionals, getting exposure through an tracker provides a less bumpy (although bumpier than the S&P 500) ride.
As well as getting sector diversification, investors gaining exposure to the index also benefit from broader equity diversification, because biotech tends to move independently from other equity sectors and indices.
A cost-effective way to track the NBI is through the iShares Nasdaq US Biotechnology ETF (BTEK) which has an ongoing charge of 0.35% a year.
Top holdings include Moderna, human therapeutics giant Amgen (AMGN:NASDAQ), software and analytics firm Vertex VERX:NASDAQ) and Gilead Sciences (GILD:NASDAQ).
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Feature
Great Ideas
News
- Greggs experiences some growing pains but there is no cause for alarm
- Federal Trade Commission lawsuit could be the first step in an Amazon break up
- The UK stock market is almost back on top in the European rankings
- Why Digital 9 Infrastructure’s shares are down 60% over one year
- Future shares jump 20% as publisher paints improved full-year picture
- Could a wet summer derail recovery at Wetherspoons?
- Soft drink and snack giant PepsiCo's earnings have surprised positively twice this year